This site is intended for Healthcare professionals only.

Aurobindo Pharma receives USFDA Approval for Levetiracetam in Sodium Chloride Injection


Aurobindo Pharma receives USFDA Approval for Levetiracetam in Sodium Chloride Injection
Hyderabad : Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Levetiracetam in Sodium Chloride Injection, 500 mg/100 mL (5 mg/mL), 1000 mg/100 mL (10 mg/mL), and 1500 mg/100 mL (15 mg/mL) (Single-use bags). Aurobindo’s Levetiracetam in Sodium Chloride Injection is a generic equivalent of HQ Specialty Pharma Corp’s Levetiracetam in Sodium Chloride Injection. The product will be launched in Jan 2017.
Levetiracetam in Sodium Chloride Injection is a CNS drug and indicated for partial onset seizures in adults (16 years and older) with epilepsy; myoclonic seizures in adults with juvenile myoclonic epilepsy; primary generalized tonic-clonic seizures in adults with idiopathic generalized epilepsy. The approved product has an estimated market size of US$ 32 million for the twelve months ending November 2016 according to IMS.
This is the 41st ANDA (including 2 tentative approvals) to be approved out of Unit IV formulation facility in Hyderabad, India used for manufacturing general injectable products. Aurobindo now has a total of 304 ANDA approvals (263 Final approvals including 16 from Aurolife Pharma LLC and 41 tentative approvals) from USFDA.



Source: Press Release
0 comment(s) on Aurobindo Pharma receives USFDA Approval for Levetiracetam in Sodium Chloride Injection

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted